Goal. The study of the clinical efficacy of combined use of systematic physical training (PT) and a fixed combination of a blocker of receptors for angiotensin II (ARB), valsartanum (Val) to dihydropyridine calcium antagonist (AA) with amlodipine (AML), appointed as part of standard therapy for smokers in patients with cardio-pulmonary pathology outpatient (III) stage of rehabilitation. Material. The study included 30 men aged 40 to 65 years. All patients were treated with statins, aspirin, .-blockers, selective and systematic FT performed 3 times a week for 4 months (duration of the training - 60 minutes with a period of moderate intensity training load of 50-60% of the threshold power cycling). After randomization, patients were divided into two groups: Group 1 (n=12) received additional angiotensin converting enzyme inhibitors (ACEI) and 2nd (n=18) - the combined preparation Exforge ® (AML 5-10 mg/Val 60 mg). Study duration - 4 months. Methods. In a study conducted clinical examination, bicycle stress test (VEM-test), echocardiography (echocardiography), ambulatory blood pressure monitoring (ABPM), spirometry, determination of concentrations of lipids and lipoproteins, glucose, fibrinogen, uric acid, creatinine, a calculation of glomerular filtration rate by MDRD. They used questionnaires: Hospital Anxiety and Depression Scale (HADS), St George's Hospital (SGRQ) and quality of life (QOL) SF-36. Results. Against the background of the FT, combined with taking an ACE inhibitor or a fixed combination of AML/Val, reduced the number of smoked cigarettes at 20.8±5.2 pieces (<0.001) and 25.6±4.2 pieces (<0.001), respectively. Also, there was a significant decrease in heart rate: in the group of ACE inhibitors on the FT+3,7±4,4 beats/min in group FT+AML/Val at 6.4±4.1 beats/min (p=0,09 between groups). Reveals reduction of office blood pressure (BP): systolic blood pressure (SBP) at 37.3±6.3 mm Hg (p<0,001) in the FT+ACEI and 36.1±6.9 mm Hg (p<0.001) in the FT+AML Val, diastolic blood pressure (DBP) at 19.6±3.9 mm Hg (p<0,001) and 18.2±4.4 mm Hg (p<0.001), respectively. According ABPM smokers and train patients on therapy AML/Val group when compared with FT+ACEI noted a marked decrease in the average daily maximum SBP (-3 mm Hg, p<0.05), daily (at -4, 4 mm Hg, p<0.05) and the night (to -1,2 mm Hg, p<0.05) and diastolic blood pressure variability in the night hours (-1.6 mm Hg, p<0.05). After 4 months of receiving FT was observed in the growth of the basic parameters of physical performance to a greater extent in the treatment of AML/shaft against receiving ACE inhibitors: FN capacity by 51.4% (p<0.001) and 32.3% (p<0.001), with a total length of FN by 51.6% (p<0.001) and 41,4% (p<0.001). Time to development of angina attack at HEM-sample after the FT in treated AML/Val increased to a greater extent (29.1%, p<0.05) against taking ACE inhibitor therapy. Both groups noted positive changes in the structural and functional parameters of the heart according to echocardiography due to lower average pressure in the pulmonary artery. In both groups there was an improvement of function parameters of external respiration, but to a greater extent in the group FT+AML/Val, as well as indicators of psychological status and quality of life. Conclusion. The inclusion of patients with a very high risk of cardiovascular events with comorbid disorders in the short (4 month) physical rehabilitation program phase III (on an outpatient basis) gives a positive clinical effect, worse when its combined with cardioprotective therapy (ACE inhibitors or AK/ARBs). This effect was most pronounced when joining the FT fixed combination of AML/Val.